Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
1
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
2
Cancer Center, Kumamoto University Hospital, Kumamoto 860-8556, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Peter J. K. Kuppen
Int. J. Mol. Sci. 2017, 18(4), 752; https://doi.org/10.3390/ijms18040752
Received: 7 March 2017
/
Revised: 25 March 2017
/
Accepted: 28 March 2017
/
Published: 2 April 2017
(This article belongs to the Special Issue Latest Advances in Colorectal Cancer Research: Molecular Mechanisms and Therapies)
Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking RAS mutations. New technologies such as liquid biopsy and next-generation sequencing have revealed that potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of KRAS and the EGFR ectodomain. Mutations in cross-talking molecular effectors that participate in downstream EGFR signaling are also negative predictors for anti-EGFR therapy. In the current review, we describe recent advances in anti-EGFR therapy and discuss new treatment strategies to target downstream RAS-MAPK signaling in mCRC.
View Full-Text
Keywords:
metastatic colorectal cancer; epidermal growth-factor receptor signaling (EGFR); chemotherapy; secondary resistance
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Miyamoto, Y.; Suyama, K.; Baba, H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int. J. Mol. Sci. 2017, 18, 752. https://doi.org/10.3390/ijms18040752
AMA Style
Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 2017; 18(4):752. https://doi.org/10.3390/ijms18040752
Chicago/Turabian StyleMiyamoto, Yuji, Koichi Suyama, and Hideo Baba. 2017. "Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer" International Journal of Molecular Sciences 18, no. 4: 752. https://doi.org/10.3390/ijms18040752
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
